Schilke Tobin
Chief Financial & Infra. Ofcr.
Schilke Tobin has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, Schilke Tobin is listed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc. Inside the rolling window, Schilke Tobin reported no open-market purchases and 1 open-market sale totaling $266K in CRNX.
Companies traded
Other insiders at CRNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$266K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Schilke Tobin made?
Schilke Tobin has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Schilke Tobin trade?
Schilke Tobin has filed SEC Form 4 disclosures for 1 company, including CRNX.
When was Schilke Tobin's most recent SEC Form 4 filing?
Schilke Tobin's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is Schilke Tobin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Schilke Tobin is listed as Chief Financial & Infra. Ofcr..
What is Schilke Tobin's total buy and sell value in the current window?
Inside the rolling retention window, Schilke Tobin bought $0 and sold $266K based on SEC Form 4 filings.
What was Schilke Tobin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,713 CRNX shares on 2026-03-03, worth $266K, per SEC Form 4 filings.